Abstract
Affect variability is determined by how often and how strongly negative affect changes over time. Cisgender women report greater variability in affect than cisgender men. It has been suggested that sex hormone changes may influence affect variability. Transgender people frequently opt to use sex hormones in the form of gender-affirming hormone therapy (GAHT), but the extent to which GAHT can change negative affect variability is not yet clear. Therefore, this study aims to study changes in negative affect variability after starting GAHT.
We have included data from 94 participants from the RESTED study: 49 transmasculine (TM) participants (assigned female at birth, starting testosterone) and 45 transfeminine (TF) participants (assigned male at birth, starting estrogens and anti-androgens). Participants completed up to 7 consecutive daily diaries at each of three time points: before starting GAHT, and after 3 and 12 months of GAHT. The daily diaries collected participants’ reports on symptoms related to negative affect: experienced low mood, less interest, tense feelings and restless feelings. We have used linear mixed models to compare negative affect variability during one week, corrected for mean negative affect, between gender groups (TM versus TF) and measurement time points.
Results show that in the TM group, variability in low mood, tense feelings and restless feelings decreases after 12 months of GAHT. In the TF group, variability in low mood increases after 3 months and 12 months of GAHT, as does variability in restless feelings after 3 months of GAHT. Group comparisons indicate significant group differences in changes in variability in low mood and restless feelings, with stronger increases in variability of negative affect in the TF group compared to TM group after 3 and 12 months of GAHT.
Our findings indicate that variability patterns in negative affect in transgender persons tend to cross- over from being consistent with sex assigned at birth before GAHT to being more in line with gender identity after 12 months of GAHT. Future studies should focus on measuring both negative and positive affect variability during GAHT, preferably through multiple measurements per day, taking into account diverse social and daily contextual factors during GAHT.
Graphical abstract
◦ Cisgender women report greater affect variability than cisgender men.
◦ The impact of GAHT on affect variability in transgender people is unclear.
◦ We examined affect variability in transmasculine (TM) and transfeminine (TF) people.
◦ We find decreased variability in negative affect after starting masculinizing GAHT.
◦ We find increased variability in negative affect after starting feminizing GAHT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Veni grant supplied by ZonMW/Netherlands Organisation for Health Research and Development to BB (91619085, 2018) and an ERC Starting Grant supplied by the European Research Council to DD (ERC-StG 101042028).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the medical ethical committee of the Amsterdam UMC (location VUmc), which declared that the Medical Research Involving Human Subjects Act (WMO) did not apply (study number 2019.353).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Since data of this study contains patient data from a vulnerable group (i.e., transgender participants), anonymized study data is available upon reasonable request by contacting the corresponding author. The study codebook and analysis code for all analyses is available via osf.io/8dnjp/.
